Nantong tumor hospital

Nantong, Jiangsu 226361

3 studies enrolling now · 13 studies all time

What they study most

Cancer, Cancer of the Prostate, Hand-Foot Skin Reaction (HFSR), Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC), Hormone Sensitive Prostate Cancer, Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer, Non-Small Cell Lung Cancer, Non-muscle Invasive Bladder Cancer, Non-small Cell Lung Cancer (NSCLC)

Studies at this site

• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. — Recruiting now
• Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) — Recruiting now
• A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Running, not enrolling
• A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — Running, not enrolling
• Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC — Running, not enrolling
• Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer — Running, not enrolling
• Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC — Completed
• A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). — Running, not enrolling
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC — Running, not enrolling
• A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer — Running, not enrolling
• A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma — Completed
• A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients — Status unconfirmed